AR016350A1 - Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos - Google Patents

Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos

Info

Publication number
AR016350A1
AR016350A1 ARP980103482A ARP980103482A AR016350A1 AR 016350 A1 AR016350 A1 AR 016350A1 AR P980103482 A ARP980103482 A AR P980103482A AR P980103482 A ARP980103482 A AR P980103482A AR 016350 A1 AR016350 A1 AR 016350A1
Authority
AR
Argentina
Prior art keywords
insulin
agent
heritage
alfa
secretagog
Prior art date
Application number
ARP980103482A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR016350A1 publication Critical patent/AR016350A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucémico inhibidor de alfa-glucosidasa, para preparar un medicamentoutil para el tratamiento de la diabetes mellitus y las condiciones asociadas con la diabetes mellitus que comprende una cantidad eficaz no toxica yfarmacéuticamente aceptable de dichos compuestos y al menos un vehículo farmacéuticamente aceptable.
ARP980103482A 1997-07-18 1998-07-16 Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos AR016350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
AR016350A1 true AR016350A1 (es) 2001-07-04

Family

ID=10816170

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980103482A AR016350A1 (es) 1997-07-18 1998-07-16 Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
ARP990103110A AR019724A2 (es) 1997-07-18 1999-06-28 Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990103110A AR019724A2 (es) 1997-07-18 1999-06-28 Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas

Country Status (27)

Country Link
EP (1) EP1001784A1 (es)
JP (1) JP2001510160A (es)
KR (1) KR20010021952A (es)
CN (1) CN1263467A (es)
AP (1) AP2000001735A0 (es)
AR (2) AR016350A1 (es)
AU (1) AU8449098A (es)
BG (1) BG104062A (es)
BR (1) BR9810292A (es)
CA (1) CA2297133A1 (es)
CO (1) CO4940489A1 (es)
DZ (1) DZ2563A1 (es)
EA (1) EA200000140A1 (es)
GB (1) GB9715298D0 (es)
HU (1) HUP0003626A3 (es)
ID (1) ID23804A (es)
IL (1) IL133907A0 (es)
MA (1) MA24608A1 (es)
NO (1) NO20000230D0 (es)
OA (1) OA11312A (es)
PE (1) PE99499A1 (es)
PL (1) PL338140A1 (es)
SK (1) SK612000A3 (es)
TR (1) TR200000133T2 (es)
UY (1) UY25101A1 (es)
WO (1) WO1999003478A1 (es)
ZA (1) ZA986364B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
BRPI0107715B8 (pt) * 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
WO2001062295A1 (fr) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Medicaments contenant des ingredients actifs combines
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
PE99499A1 (es) 1999-12-18
MA24608A1 (fr) 1999-04-01
AU8449098A (en) 1999-02-10
JP2001510160A (ja) 2001-07-31
UY25101A1 (es) 2000-12-29
BG104062A (en) 2000-11-30
ZA986364B (en) 2000-01-17
WO1999003478A1 (en) 1999-01-28
DZ2563A1 (fr) 2003-02-15
CA2297133A1 (en) 1999-01-28
EA200000140A1 (ru) 2000-06-26
AR019724A2 (es) 2002-03-13
ID23804A (id) 2000-05-11
OA11312A (en) 2003-10-24
PL338140A1 (en) 2000-09-25
NO20000230L (no) 2000-01-17
CN1263467A (zh) 2000-08-16
HUP0003626A3 (en) 2001-12-28
BR9810292A (pt) 2000-09-19
KR20010021952A (ko) 2001-03-15
NO20000230D0 (no) 2000-01-17
SK612000A3 (en) 2000-07-11
IL133907A0 (en) 2001-04-30
GB9715298D0 (en) 1997-09-24
EP1001784A1 (en) 2000-05-24
TR200000133T2 (tr) 2000-09-21
HUP0003626A2 (hu) 2001-05-28
AP2000001735A0 (en) 2000-01-16
CO4940489A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
NO20090846L (no) Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
AR016350A1 (es) Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
UY25800A1 (es) Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
CO4940454A1 (es) Nuevo metodo de tratamiento
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
ES2176702T3 (es) Antimicoticos con alta liberacion de sustancia activa.
HUP0104388A2 (hu) Béta-agonistákból és további antidiabetikus szerekből álló kombinációk
ECSP982541A (es) Nuevo metodo de tratamiento ii
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
ECSP982593A (es) Nuevo metodo de tratamiento vi
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.
ECSP982592A (es) Nuevo metodo de tratamiento v
ECSP982591A (es) Nuevo metodo de tratamiento iv
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982542A (es) Nuevo metodo de tratamiento iii
AR001807A1 (es) Formulación de gel de podofilox
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
BR9815219A (pt) Uso de tiazolidinedionas para o tratamento da hiperglicemia

Legal Events

Date Code Title Description
FB Suspension of granting procedure